Zacks Industry Outlook Highlights: The Medicines Company, Optimer Pharma and Cubist Pharma

 Zacks Industry Outlook Highlights: The Medicines Company, Optimer Pharma and
                                Cubist Pharma

PR Newswire

CHICAGO, Dec. 7, 2012

CHICAGO, Dec. 7, 2012 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. Pharma & Biotech, including The Medicines Company (Nasdaq:MDCO),
Optimer Pharma (Nasdaq:OPTR) and Cubist Pharma (Nasdaq:CBST).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

A synopsis of today's Industry Outlook is presented below. The full article
can be read at 

http://www.zacks.com/commentary/24869/pharma--biotech-stock-outlook-dec-2012

A major event that will have a significant impact on pharma and biotech stocks
is the upholding of the Patient Protection and Affordable Care Act (ACA) by
the Supreme Court in late June 2012. The Act, popularly referred to as
"Obamacare," passed through Congress in 2010, represents major changes in the
nation's healthcare sector.

The Act will provide coverage to 32 million uninsured Americans, make
healthcare facilities more affordable, expand coverage for customers with
pre-existing health conditions and keep a check on health insurers. The
healthcare reform aims to end the discrimination policy of insurance
companies, create competition amongst insurers through the establishment of
health insurance exchanges, add value to the overall healthcare system and
reduce premiums.

The upholding of the Act is a big win for pharma companies as the coverage
base will increase.

Meanwhile, the signing of the Gaining Antiobiotic Incentives Now (GAIN) Act
should benefit companies pursuing the development of novel antibiotics. Once
approved, these products will enjoy an additional five years of marketing
exclusivity. Companies that should benefit from this Act include

The Medicines Company

(Nasdaq:

MDCO

),

Optimer Pharma

(Nasdaq:

OPTR

) and

Cubist Pharma

(Nasdaq:

CBST

) among others.

The US government is also exploring options which will help increase the
availability of generics. The Obama administration announced that it is
looking to implement a proposal under which the exclusivity period for
biologics will be cut down by 5 years, thereby allowing generics to enter the
market sooner.

The government is also seeking to increase the availability of generics by
preventing companies from entering into anti-competitive or "pay for delay"
agreements which push out the availability of generics. These initiatives, if
implemented, would result in additional pricing competition and genericization
in the pharma industry. Moreover, the establishment of a biosimilar pathway
will lead to the availability of cheaper versions of biologics.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com